PROGNOSIS OF RESPONSE TO TREATMENT WITH ANTI-TNF-ALPHA IN PATIENTS WITH RHEUMATOID ARTHRITIS

摘要

The invention relates to the use of SNP rs3794271, and/or an SNP that is in total linkage disequilibrium with same, as a marker in predicting the response to treatment with anti-TNF in a patient with RA. The invention also relates to methods for predicting the response to treatment with anti-TNF, as well as for deciding on or recommending a treatment for a patient with RA, based on determining the genotype for rs3794271 and/or an SNP that is in total linkage disequilibrium with same.

主权项

1. An in vitro method for the prediction of the response of a patient with rheumatoid arthritis (RA) to treatment with tumor necrosis factor inhibitor alpha (anti-TNF alpha agent) selected between infliximab or etanercept that comprises determining, from a sample obtained from the patient, the genotype for single nucleotide polymorphism (SNP) rs3794271, and/or at least one SNP that is in linkage disequilibrium with SNP rs3794271, wherein:
i. the presence of at least one G allele at SNP rs3794271 is indicative of a bad response to treatment while the presence of two alleles other than G at SNP rs3794271 is indicative of a good response to therapy; and/or ii. the presence of at least one allele correlated with the G allele at SNP rs3794271 for the SNP in linkage disequilibrium is indicative of a bad response to treatment while the presence of two alleles not correlated with the G allele at SNP rs3794271 for the SNP in linkage disequilibrium is indicative of a good response to treatment.